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CNP signal peptide in patients with
cardiovascular disease
Jacqui Lee, Martin Than, Sally Aldous, Richard Troughton, Mark Richards and
Chris J. Pemberton*
Department of Medicine, Christchurch Heart Institute, University of Otago, Christchurch, New Zealand
We have previously reported that signal peptide fragments of C-type natriuretic peptide
(CNP) are present in the human circulation. Here, we provide the first preliminary
assessment of the potential utility of CNP signal peptide (CNPsp) measurement in acute
cardiovascular disease. Utilizing our specific and sensitive immunoassay, we assessed
the potential of CNPsp measurement to assist in the identification of acute coronary
syndromes in 494 patients presenting consecutively with chest pain. The diagnostic
and prognostic potential of CNPsp were assessed in conjunction with a contemporary
clinical troponin I assay, an investigational highly sensitive troponin T assay and NT-
proBNP measurement. Utility was assessed via receiver operator curve characteristic
analysis. CNPsp did not identify patients with myocardial infarction (MI) or those with
unstable angina, nor did it assist the diagnostic ability of clinical or investigational troponin
measurement. CNPsp levels were significantly elevated in patients presenting with atrial
fibrillation (P<0.05) and were significantly lower in those with a history of previous MI
(P<0.05). CNPsp could identify those at risk of mortality within 1 year (P<0.05) and
also could identify those at risk of death or re-infarction within 1 year (P<0.01). This
is the first exploratory report describing the potential of CNPsp measurement in acute
cardiovascular disease. While CNPsp does not have utility in acute diagnosis, it may have
potential in assisting risk prognosis with respect to mortality and re-infarction.
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Introduction
Wehave recently reported that signal peptide (SP) fragments derived from each of A-type natriuretic
peptide (ANP), B-type natriuretic peptide (BNP), and C-type natriuretic peptide (CNP) are present
in the human circulation (1–3). Each of these fragments derives from the carboxyl terminus of their
respective signal peptide and all of them bear biochemical adducts of differing sizes. In normal
healthy individuals, plasma levels of each SP do not correlate with their propeptide siblings and
they also respond differently during the course of ST-elevation myocardial infarction (STEMI). All
three SP do show evidence of cardiac secretion and this raises the possibility that their measurement
in plasma may have utility in cardiovascular disease.
Whereas circulating concentrations of ANP and BNP are predominately influenced by cardiac
secretion (1, 2), CNP gene-derived peptides appear to be secreted from multiple organs and are
Abbreviations: AF, atrial fibrillation; CNP, C-type natriuretic peptide; CNPsp, C-type natriuretic peptide signal peptide;
STEMI, ST-elevation myocardial infarction; UA, unstable angina.
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thought to be more reliant on general vascular release (4). By con-
trast, our previous report (3) suggested that plasma concentrations
of CNP signal peptide (CNPsp) may be more reliant on cardiac
and renal production and that plasma levels of CNPsp were raised
in patients suffering STEMI. Given this background, we now
report preliminary, exploratory findings on CNPsp measurement
in patients with chest pain suggestive of an acute coronary syn-
drome (ACS), presenting to single center, hospital emergency
department. The aim of this work was to determine if CNPsp
measurement might have potential utility in the diagnosis and/or
prognosis of patients with chest pain.
Materials and Methods
Blood Sample Collection
Prospective Chest Pain Study
For this study, patients presenting to Christchurch Hospital with
the primary complaint of chest pain <4 h duration were offered
recruitment into our prospective, observational study known as
signal peptides in acute coronary events (SPACE, http://www.
anzctr.org.au, ACTRN12609000057280). Patients with the pri-
mary complaint of acute chest, epigastric, neck, jaw, or arm pain
suspicious of ACS, without obvious non-cardiac origin, and last-
ing 20min were enrolled in accord with guideline definitions
(5). More general/atypical symptoms (such as fatigue, nausea,
vomiting, sweating, and faintness) were not used as inclusion
criteria and those on dialysis or with terminal kidney failure
were excluded. EDTA blood samples for measurement of hsTnT,
proBNP, andCNPsp andHeparin blood samples formeasurement
of TnI were taken at time 0, 1, 2, and 12–24 h after presentation.
The adjudicated diagnosis of acute MI was made in accordance
with the 2012 ESC/ACCF/AHA/WHF taskforce guidelines (6),
by two independent cardiologists with access to all clinical data
but not CNPsp or hsTnT. The biochemical component of the
diagnosis of MI was made using a late generation TnI assay with
1 value99th URL (99th percentile= 0.03µg/L) and a rise or fall
of 50% of the URL (=0.015µg/L) within 12 h of presentation.
Follow Up and Prognostic End Points
At 45 and 365 days post-discharge from hospital, consented and
enrolled patients in the ACS study were contacted by telephone
or in writing to complete a follow up interview/questionnaire.
Reported clinical events were identified from the patients them-
selves (or their primary physician) and confirmed by clinical adju-
dication, centralized New Zealand Ministry of Health database
registry entries on mortality and events and with records of the
treating institution. The prognostic end points considered were
mortality, subsequent MI, subsequent episode of acute decom-
pensated heart failure (ADHF), and subsequent stroke. We also
considered the composite end point of mortality or MI within
365 days.
CNPsp and Cardiac Marker Assays
CNP signal peptide was measured using our in-house immunoas-
say, as previously reported (3). Briefly, extracted plasma samples
and standards were diluted in assay buffer, with the assay incubate
consisting of 50µL of sample or standard (0–3,630 pmol/L of
CNPsp peptide) mixed with 50µl of antibody at 1:8000 dilution
and left to incubate for 22 h at 4°C. Fifty microliters of iodinated
CNPsp(Tyr) trace peptide (~3000 cpm) were then added and left
to incubate for a further 22 h at 4°C. Free and bound CNPsp
were then separated by solid-phase second antibody method
(donkey anti-sheep SacCel, Immunodiagnostic Systems, Boldon,
UK) in 2% polyethylene glycol/phosphate buffer (final Sac-Cel
concentration 5%) at room temperature for 30min. Tubes were
then centrifuged at 2800 g for 15min, the supernatant decanted
and pellet counted in a Gammamaster counter (LKB, Uppsala,
Sweden). CNPsp immunoreactivity is neither altered by hemolysis
up to 8 g/L nor by plasma lipid at up to 15 g/L. The limit of
sample detection for this assay is 5 pmol/L, an ED50 of 284 pmol/L
and a 99th percentile upper limit of normal range of 130 pmol/L
(n= 109). The intra-assay CV is <7% with inter-assay CVs at 22%
at 200 pmol/L and 11% at 780 pmol/L (3).
proBNP was determined by in-house immunoassay (7, 8). TnI
was determined by a late generation assay (Abbott Architect)
with a 99th percentile cut-off of 0.03µg/L. Investigational TnT
values were determined using a high-sensitivity assay (Elecsys
2010 analyzer, Roche Diagnostics) with a 99th percentile cut-off
of 14 pg/mL. All hsTnT results were submitted to Penzberg during
the worldwide reassessment of hsTnT by Roche (9), and only three
required adjustment, all of which were below 14 pg/mL.
Statistics
Continuous variables are presented asmedian [interquartile range
(IQR)] whereas categorical variables are numbers and percent-
ages. Continuous variables were analyzed by Mann–Whitney U
test and categorical variables by Pearson χ2 test. Relational analy-
sis of plasma analyte concentrations using Spearman rank order
correlation testing and receiver operator curve (ROC) analysis
were carried out using SPSS v22 (IBM). For ROC curve generation
and biomarker panel comparisons, biomarker data were analyzed
as descriptive standardized variables (z-scores). In all cases, the
standardized variable was derived from the maximum biomarker
value obtained from the t= 0, 1, and 2 h samples, i.e., the max-
imum of the three values. ROC curve comparisons were done
according to Hanley and McNeill (10). In all analyses, a P-value
<0.05 was considered significant.
Results
Patient Characteristics
A total of 494 patients were enrolled in this study. Demographic
data for this group are given in Table 1. Approximately 23% of
patients had final adjudicated diagnosis of myocardial infarction
(MI), 8% had definitive unstable angina (UA), 5% had other
cardiac disorders (such as arrhythmia, sick sinus syndrome, heart
failure), and 64%had chest pain of non-cardiac origin. All patients
completed 45- and 365-day follow up. Respectively,mortality rates
at 45 and 365 days were 1% (n= 4) and 4% (n= 18); subsequent
MI 2% (n= 10) and 5.7% (n= 28); subsequent episode of ADHF
0.6% (n= 3) and 2% (n= 10); subsequent stroke 1% (n= 4) and
2% (n= 10). The composite end-point of death or MI at 365 days
was 9% (n= 44).
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Patient, no. (%) 112 (23) 39 (8) 24 (5) 319 (64) 494 (100)
Gender, no. (%)
Male 76 (68) 25 (64) 14 (58) 181 (57) 296 (60)
Female 36 (32) 14 (36) 10 (42) 138 (43) 198 (40)
Age (years)
Male 66 (56–76) 64 (58–70) 64 (52–77) 59 (48–70) 62 (51–70)
Female 77 (68–86) 66 (59–73) 72 (65–80) 69 (58–80) 69 (59–80)
Analytes
Chol (mgdL 1)a 180 (154–216) 172 (141–213) 183 (157–201) 189 (154–215) 185 (154–216)
HDL (mgdL 1)a 41 (34–50) 38 (35–42) 41 (30–58) 44 (37–53) 42 (36–51)
LDL (mgdL 1)a 112 (93–143) 104 (77–139) 100 (84–124) 112 (89–135) 112 (89–135)
Trig (mgdL 1)b 142 (97–195) 128 (95–177) 142 (88–181) 124 (97–186) 133 (97–186)
BMI (kgm2) 27:7 (24:7–31:3) 27:2 (25:1–30:3) 27:7 (24:6–31:8) 27:7 (24:9–31:3) 27:7 (24:7–31:1)
Risk factor (%)
Hypertension 78 (70) 33 (85) 20 (83) 192 (60) 323 (65)
Diabetes 19 (17) 9 (23) 4 (17) 43 (13) 75 (15)
Current smoker 16 (14) 2 (5) 0 (0) 44 (14) 62 (13)
Ever smoker 56 (50) 21 (54) 19 (79) 157 (49) 253 (50)
History (%)
CVD 78 (70) 36 (92) 13 (54) 199 (62) 326 (65)
MI 36 (32) 20 (51) 10 (42) 99 (31) 165 (33)
CABG 9 (8) 6 (15) 3 (13) 35 (11) 53 (10)
Hyperlipidemia 62 (55) 34 (87) 14 (58) 193 (61) 303 (60)
Angina 48 (43) 30 (77) 17 (71) 158 (50) 253 (50)
Heart failure 10 (9) 4 (10) 2 (8) 33 (10) 49 (10)
ECG results (%)
LBBB 2 (2) 1 (3) 1 (4) 7 (2) 11 (2)
ST-elevation 22 (20) 0 (0) 2 (8) 0 (0) 24 (5)
ST-depression 10 (9) 1 (3) 3 (13) 2 (1) 16 (3)
T-wave inversion 20 (18) 5 (13) 6 (25) 30 (9) 61 (12)
No change 56 (50) 31 (79) 14 (58) 281 (88) 382 (78)
Presentation marker levels
hsTnT (ng/L) 79 (37–219) 6 (3–10) 22 (8–36) 5 (3–12) 8 (3–27) <0:01
TnI (ug/L) 0:25 (0:07–1:30) 0:01 (0:01–0:01) 0:02 (0:01–0:04) 0:01 (0:01–0:01) 0:01 (0:01–0:03) <0:01
CNPsp (ng/L) 51:8 (45:7–67:3) 51:6 (42:1–62:0) 54:3 (46:5–66:4) 50:1 (42:3–62:2) 50:6 (42:7–63:1) NS
NTproBNP (ng/L) 87 (32–166) 50 (33–166) 133 (51–231) 39 (18–88) 45 (21–122) <0:01
aTo convert mgdL 1 cholesterol to mmol/L, multiply by 0.0259.
bTo convert mgdL 1 triglycerides to mmol/L, multiply by 0.0113.
Presentation Levels of CNPsp, proBNP, and
Troponin
Presentation CNPsp levels had significant positive correla-
tions with ECG ST-segment depression (r= 0.105, P< 0.05),
HDL (r= 0.132, P< 0.01), and sodium (r= 0.116, P< 0.05),
but had significantly negative correlations with respiratory rate
(R= 0.104, P< 0.05) and plasma creatinine ( 0.125, P< 0.01).
CNPsp had no correlation with proBNP, TnI, or hsTnT. Plasma
levels of hsTnT, TnI, proBNP, and CNPsp dissected by adjudi-
cated diagnosis are shown in Table 1. Whereas proBNP, hsTnT,
and TnI levels were clearly and significantly elevated in patients
suffering either MI or other cardiac disorders (Table 1, P< 0.01),
CNPsp levels were not changed in these groups. Instead, CNPsp
levels were significantly elevated in those patients whom had
evidence of atrial fibrillation (AF, n= 19) during their emergency
department presentation [median AF, 58.5 (48.6–69.3) vs. median
non-AF 50.4 (42.7–63.0), P< 0.05, Figure 1A] whereas they were
significantly lower in those with a history of previous MI [median
previous MI (n= 153), 47.8 (40.7–56.9) vs. non-MI (n= 341),
49.3 (41.9–64.3) P< 0.05, Figure 1B]. Of note, median CNPsp
levels in AF patients without a history ofMI (n= 11, 60.2 pmol/L)
were higher than those in patient with a history of MI (n= 8,
57.0 pmol/L).
ROC Analyses of CNPsp vs. Other Cardiac
Markers
As expected, cardiac TnI (AUC= 0.974, 95% CI 0.957–0.992,
P< 0.001) and hsTnT (AUC= 0.959, 95%CI 0.941–0.977,
P< 0.001) had excellent ability to identify acute MI (Figure 2).
By contrast, CNPsp did not generate significant ROC curves for
any of MI (AUC= 0.56, 95% CI 0.496–0.614, P= 0.07, Figure 2),
UA (AUC= 0.51, P= 0.518) or alternate cardiac disorders
(AUC= 0.59, P= 0.16). Furthermore, CNPsp concentrations
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FIGURE 1 | Plasma concentrations (median, IQR) of CNPsp (ng/L) in patients with and without atrial fibrillation (AF) (A) and those with and without a
previous history of MI (B). *Indicates statistical significance (P<0.05) by non-parametric testing.
FIGURE 2 | Receiver operator curve curves for the identification of MI
(n=112) in the chest pain study group. Clinical TnI and investigational
hsTnT assays performed similarly (both P<0.001). CNPsp measurement did
not generate a significant AUC (0.56, P= 0.07) for the identification of MI and
did not add to TnI or hsTnT measurement.
did not add to AUC or specificity/sensitivity values for either
troponin.
Prognostic Ability of CNPsp
In the whole study group, a presentation concentration of CNPsp
<52 ng/L predicted death (n= 18) at 1 year (AUC= 0.663, 95%CI
0.563–0.764, P= 0.019, Figure 3A) and also predicted a compos-
ite end-point of death/MI (n= 44) at 1 year (AUC= 0.631, 95%
CI 0.560–0.706, P< 0.01, Figure 3B). Combining CNPsp with
proBNP improved the proBNPAUC for 1 yearmortality from0.77
to 0.82 and the composite end-point of death/MI AUC from 0.73
to 0.77, but neither of these improvements were significant.
In patients suffering MI (n= 112), CNPsp alone did not gen-
erate a significant AUC for any future event. However, adding
CNPsp to proBNP improved the proBNP AUC for MI within one
year (n= 12) from0.647 (95%CI, 0.488–0.805,P= 0.098) to 0.707
(95% CI, 0.563–0.850, P= 0.020). In non-MI patients (n= 382),
addition of CNPsp improved theAUCof proBNP for prediction of
death at 1 year (n= 12) from 0.766 to 0.833 (95% CI, 0.747–0.920,
P< 0.001), again a non-significant improvement.
Discussion
The major findings of this work are (i) CNPsp does not identify
ACS in patients with chest pain or those with alternate disor-
ders such as myopathies/valve disease as assessed by ROC AUC
analysis; (ii) CNPsp levels are significantly elevated in patients
presenting with AF, yet significantly lower in those with previous
history of MI; (iii) if CNPsp measurement has any utility at all in
ACS, it may possibly be found in assisting NT-proBNP-based risk
assessment of future major adverse events.
The lack of CNPsp to generate ROC significance in MI is con-
sistent with our earlier data, which indicated that CNPsp did not
display much of a dynamic range in patients suffering STEMI (3).
Comparison with CNP and NT-proCNP is difficult as there are
few reports that have described the acute response of CNP or NT-
proCNP during MI. CNP has been studied loosely in the context
of MI patients (11), did not show much dynamism in the early
hours after MI and also displayed less powerful prognostic ability
up to 2 years post-MI, compared with BNP and ANP. Part of this
point of difference probably largely stems from the ubiquitous
nature of CNP secretion, which comes frommultiple sources, not
just cardiac (4) and also that circulating CNP concentrations tend
to be much lower compared with ANP and BNP. In this regard,
CNPsp tends to display a secretion pattern more like that of NT-
proCNP in that renal and cardiac venous drainage contains high-
est amounts of both peptides (3, 4), but this still does not translate
into useful performance characteristics in chest pain patients.
Combining this secretion profile with the weak, but significant,
negative correlation with plasma creatinine, it seems probable that
CNPsp concentrations are markedly influenced by renal status.
The underlying mechanism and relevance of elevations in
CNPsp concentrations in patients with AF is unclear but is
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FIGURE 3 | Presentation CNPsp levels lower than 52ng/L could generate significant AUC curves for the identification of death within 1 year (n=18,
AUC=0.663, P=0.019) (A) and the composite end-point of death/MI within 1 year (n=44, AUC=0.631, P< 0.01) (B).
consistent with our previous finding of a significant correlation
of arterial CNPsp with heart rate (3). Both BNP and CNP can
increase heart rate in vitro as well as increasing L-type Ca2+
channel activity and the hyperpolarization-activated current I(f ),
an effect which is reliant upon phosphodiesterase-3 presence and
activity (12). Thus, whether elevated circulating CNPsp concen-
trations in the setting of AF represents a passive response or is
indicative of a more defined biological relationship with heart rate
is a potential area for further study. Further, we cannot exclude the
potential for confounding multiple comparison issues as affecting
this result.
The ability of CNPsp to identify those at risk of death within
1 year and potentially improve the AUC of NT-proBNP identi-
fication of mortality risk is an interesting exploratory finding.
Although the data are only from a very small group, and find-
ings can only be considered as preliminary, they do suggest that
CNPsp, like CNP, is worthy of further study in risk prediction
in patients suffering chest pain. In particular, the CNPsp AUC
for mortality (0.66) is close to the 2-year mortality predictive
AUC of highly sensitive TnI assays (~0.70), which were not used
here (13). Further studies will need to address any potential for
additive utility between CNPsp and hsTnI. A single study has
suggested CNP does not appear to predict well either death or re-
infarction inMI sufferers (11) but like our present report, suffered
from small numbers. CNPdoes, however, have strong associations
with left ventricular fibrosis and subsequent systolic and diastolic
impairment (14), the development of arterial stiffness, endothelial
function, and atherosclerosis (15) and the preservation of long-
term vascular and renal function (16). Thus, future studies assess-
ing the comparative risk prediction abilities of CNP, NT-proCNP,
and CNPsp in suitably sized chest pain populations will need
to take into account vascular and renal contributions to disease
progression.
In conclusion, CNPsp measurement is unlikely to have utility
in assisting the diagnosis of MI (either STEMI or NSTEMI) or
UA in patients presenting with chest pain. CNPsp concentrations
are elevated in patients presenting with AF and the potential
biological relevance of this should be further determined in appro-
priate experimental models. Finally, CNPsp concentrations are
lower in chest pain patients with a history of previous MI and this
feature may have potential to assist in the prognosis of subsequent
mortality or MI. Appropriately designed study groups that take
into account vascular and renal contributions as well as perform
head to head comparisons with CNP and NT-proCNP, will be
needed to properly address this.
Limitations
First, our study size is satisfactory for assessing potential diagnos-
tic ability of CNPsp with respect to MI and UAP, but it can only
provide exploratory data for prognostic implications and thus any
findings are interpreted accordingly. Second, our adjudication of
MI relied on a conventional TnI assay. Incorporation of a high-
sensitivity troponin I assay may have provided subtle differences
in analyses (17). Third, whereas the half-life and clearance of pro-
CNP forms are known (18), such data for CNPsp and other signal
peptides are not available.
Author Contributions
CP, MR, RT, and MT, designed research; CP, JL, MT, and SA,
performed research; CJP, MR, and RT, analyzed data; and CP, RT,
MR, MT, SA, and JL, wrote the paper.
Acknowledgments
We thank the technical staff of Canterbury Health Laborato-
ries and Endolab, Christchurch Hospital, New Zealand for assis-
tance with biomarker assays and the research nursing staff of
the Christchurch Heart Institute for assistance with patient blood
sampling. Funding Sources: This work was supported by the
Health Research Council of New Zealand (Grant 08/070) and the
National Heart Foundation of New Zealand (Grant 1351). MR
holds the National Heart Foundation of New Zealand Professorial
Chair in Cardiovascular Studies.
Frontiers in Cardiovascular Medicine | www.frontiersin.org June 2015 | Volume 2 | Article 285
Lee et al. CNPsp in CVD patients
References
1. Siriwardena M, Kleffmann T, Ruygrok P, Cameron V, Yandle T, Nicholls G,
et al. BNP signal peptide circulates in human blood: evaluation as a potential
biomarker of cardiac ischemia. Circulation (2010) 122(3):255–64. doi:10.1161/
circulationaha.109.909937
2. Pemberton CJ, Siriwardena M, Kleffmann T, Ruygrok P, Palmer SC, Yandle
TG, et al. First identification of circulating preproANP signal peptide fragments
in man: initial assessment as cardiovascular biomarkers. Clin Chem (2012)
58(4):757–77. doi:10.1373/clinchem.2011.176990
3. Pemberton CJ, Siriwardena M, Kleffmann T, Richards AM. C-type natriuretic
peptide (CNP) signal peptide fragments are present in the human circulation.
Biochem Biophys Res Commun (2014) 449(3):301–6. doi:10.1016/j.bbrc.2014.
05.020
4. Palmer SC, Prickett TCR, Espiner EA, Yandle TG, Richards AM. Regional
release and clearance of C-type natriuretic peptides in the human circulation
and relation to cardiac function.Hypertension (2009) 54(3):612–8. doi:10.1161/
hypertensionaha.109.135608
5. Luepker RV, Apple FS, Christenson RH, Crow RS, Fortmann SP, Goff D,
et al. Case definitions for acute coronary heart disease in epidemiology and
clinical research studies.Circulation (2003) 108(20):2543–9. doi:10.1161/01.cir.
0000100560.46946.ea
6. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD,
et al. Third universal definition of myocardial infarction. Circulation (2012)
126(16):2020–35. doi:10.1161/CIR.0b013e31826e1058
7. Richards M, Nicholls MG, Espiner EA, Lainchbury JG, Troughton RW, Elliott
J, et al. Comparison of B-type natriuretic peptides for assessment of cardiac
function and prognosis in stable ischemic heart disease. J Am Coll Cardiol
(2006) 47(1):52–60. doi:10.1016/j.jacc.2005.06.085
8. Wright SP, Doughty RN, Pearl A, Gamble GD, Whalley GA, Walsh HJ, et al.
Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-
failure diagnosis in primary care: a randomized, controlled trial. J Am Coll
Cardiol (2003) 42(10):1793–800. doi:10.1016/j.jacc.2003.05.011
9. Apple F, Jaffe A. Clinical implications of a recent adjustment to the high sensitiv-
ity cardiac troponin T assay: user beware. Clin Chem (2012) 58(11):1599–600.
doi:10.1373/clinchem.2012.194985
10. Hanley JA, McNeill BJ. A method of comparing the areas under receiver
operating characteristic curves derived from the same cases. Radiology (1983)
148(3):839–43. doi:10.1148/radiology.148.3.6878708
11. Squire IB, Orn S, Ng LL, Manhenke C, Shipley L, Aarsland T, et al. Plasma
natriuretic peptides up to 2 years after acute myocardial infarction and relation
to prognosis: an OPTIMAAL substudy. J Card Fail (2005) 11(7):492–7. doi:10.
1016/j.cardfail.2005.05.004
12. Springer JL, Azer J, Hua R, Robbins C, Adamczyk A, McBoyle S, et al. The
natriuretic peptides BNP and CNP increase heart rate and electrical conduction
by stimulating ionic currents in the sinoatrial node and atrial myocardium
following activation of guanylyl cyclase-linked natriuretic peptide receptors.
J Mol Cell Cardiol (2012) 52(5):1122–34. doi:10.1016/j.yjmcc.2012.01.018
13. Haaf P, Reichlin T, Twerenbold R, Hoeller R, Rubini Gimenez M, Zellweger
C, et al. Risk stratification in patients with acute chest pain using three high-
sensitivity cardiac troponin assays. Eur Heart J (2014) 35:365–75. doi:10.1093/
eurheartj/eht218
14. Sangaralingham SJ, Huntley BK, Martin FL, McKie PM, Bellavia D, Ichiki
T, et al. The aging heart, myocardial fibrosis and its relationship to circulat-
ing C-type natriuretic peptide. Hypertension (2011) 57(2):201–7. doi:10.1161/
hypertensionaha.110.160796
15. Vlachopoulos C, Ioakeimidis N, Terentes-Printzios D, Aznaouridis K, Baou
K, Bratsas A, et al. Amino-terminal pro-C-type natriuretic peptide is asso-
ciated with arterial stiffness, endothelial function and early atherosclerosis.
Atherosclerosis (2010) 211(2):649–55. doi:10.1016/j.atherosclerosis.2010.03.020
16. Moyes AJ, Khambata RS, Villar I, Bubb KJ, Baliga RS, Lumsden NG, et al.
Endothelial C-type natriuretic peptide maintains vascular homoeostasis. J Clin
Invest (2014) 124(9):4039–51. doi:10.1172/JCI74281
17. Thygesen K, Mair J, Giannitsis E, Mueller C, Lindahl B, Blankenberg S, et al.
How to use high-sensitivity cardiac troponins in acute cardiac care. Eur Heart J
(2012) 33(18):2252–7. doi:10.1093/eurheartj/ehs154
18. Hunt PJ, Richards AM, Espiner EA, Nicholls MG, Yandle TG. Bioactivity and
metabolism of C-type natriuretic peptide in normal man. J Clin Endocrinol
Metab (1994) 78(6):1428–35. doi:10.1210/jcem.78.6.8200946
Conflict of Interest Statement: The University of Otago, New Zealand has filed
a patent application on the composition and diagnostic/prognostic use of CNPsp
measurement in cardiovascular and cardiorespiratory disorders. Chris J. Pemberton
andMark Richards are listed as inventors on this application. All other authors have
nothing to disclose.
Copyright © 2015 Lee, Than, Aldous, Troughton, Richards and Pemberton. This is an
open-access article distributed under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduction in other forums is permitted,
provided the original author(s) or licensor are credited and that the original publica-
tion in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Cardiovascular Medicine | www.frontiersin.org June 2015 | Volume 2 | Article 286
